Ustekinumab Improves Active Crohn’s Disease by Suppressing the T Helper 17 Pathway | Zendy

Yutaro Ihara | Zendy; Takehiro Torisu | Zendy; Kohta Miyawaki | Zendy; Junji Umeno | Zendy; Keisuke Kawasaki | Zendy; Atsushi Hirano | Zendy; Shin Fujioka | Zendy; Yuta Fuyuno | Zendy; Yuichi Matsuno | Zendy; Takeshi Sugio | Zendy; Kensuke Sasaki | Zendy; Tomohiko Moriyama | Zendy; Koichi Akashi | Zendy; Takanari Kitazono | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ustekinumab Improves Active Crohn’s Disease by Suppressing the T Helper 17 Pathway

Author(s) -

Yutaro Ihara,

Takehiro Torisu,

Kohta Miyawaki,

Junji Umeno,

Keisuke Kawasaki,

Atsushi Hirano,

Shin Fujioka,

Yuta Fuyuno,

Yuichi Matsuno,

Takeshi Sugio,

Kensuke Sasaki,

Tomohiko Moriyama,

Koichi Akashi,

Takanari Kitazono

Publication year - 2021

Publication title -

digestion

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.882

H-Index - 75

eISSN - 1421-9867

pISSN - 0012-2823

DOI - 10.1159/000518103

Subject(s) - ustekinumab , medicine , crohn's disease , tumor necrosis factor alpha , flow cytometry , immunology , interleukin 23 , interleukin 17 , t cell , gastroenterology , disease , cytokine , immune system , adalimumab

Ustekinumab (UST), an antibody targeting the p40 subunit of interleukin (IL)-12 and IL-23, is effective in treating Crohn's disease (CD). To clarify the mechanism of UST, we investigated T-cell differentiation in CD patients treated with UST.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research